Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR How to Discuss Your Goals of Care With Your Cancer Care... October 17, 2023 Dabrafenib Plus Trametinib Improves Efficacy in Children and Adolescents with Relapsed/Refractory... September 19, 2023 Fostering Black leadership in cancer research July 20, 2023 No Improvement in OS with Adding Palbociclib to Letrozole for the... January 24, 2024 Load more HOT NEWS Training Cancer Researchers: A Conversation with Dr. Oliver Bogler Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... A tribute to Professor Gordon McVie Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer
